Record overview
Status and phase
Status: RECRUITING
Phase: PHASE1, PHASE2
Sponsor: Phanes Therapeutics
Condition: Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
NCT05431270
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.